Categories: News

Bavarian Nordic to Host First Quarter 2022 Results Conference Call and Webcast

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

COPENHAGEN, Denmark – May 4, 2022 – Bavarian Nordic A/S (OMX:  BAVA) will announce its 2022 first quarter results on Monday, May 9, 2022.

The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will be available at https://www.bavarian-nordic.com/investor/events.aspx?event=6388.

To join the Q&A session dial one of the following numbers and state the participant code 7179801: Denmark: +45 32 72 04 17, UK: +44 (0) 844 481 9752, USA: +1 646-741-3167

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company listed on the NASDAQ Copenhagen exchange and with operations in Europe and the USA. Our mission is to save and improve lives by unlocking the power of the immune system and we aspire to become one of the largest pure play vaccine companies by developing innovative life-saving vaccines, excelling in commercialization and being a best-in-class vaccine manufacturer. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next-generation COVID-19 vaccine and a vaccine against respiratory syncytial virus (RSV), which are both entering Phase 3 clinical trials in 2022. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Tel: +45 61 77 47 43
U.S.: Graham Morrell, Paddock Circle Advisors (US), Tel: +1 781 686 9600

Staff

Recent Posts

Newly Published Health Economics Study Demonstrates In-Office Ear Tube Procedures with Hummingbird TTS Significantly Reduce Healthcare Costs

GOLDEN VALLEY, Minn.--(BUSINESS WIRE)--Preceptis Medical, Inc., a pioneer in pediatric ENT innovation, today announced the…

1 hour ago

111, Inc. Announces First Quarter 2025 Unaudited Financial Results

Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoYMaintained…

1 hour ago

As Sober.Buzz Community Explodes Its Growth Globally it is Announcing “Spreading the Good BUZZ” Podcast Hosted by Josh Case Debuting July 7th

Sober.Buzz's Online Store that includes the Exclusive Inspirational Collection by Heidi Case has Launched. Additionally,…

13 hours ago

STUDENTS STEP INTO THE ROLE OF ATHLETIC TRAINERS, CARDIOLOGISTS, DIETITIANS, AND MORE WITH FREE SUMMER SCIENCE PROGRAM!

GSK Science in the Summer™ Unveils New 2025 Theme: Be A Health Scientist! PHILADELPHIA, June…

13 hours ago

Healthy Interactions Expands Primary Care Alliance to Improve Cardiometabolic Care

JACKSON HOLE, Wyo., June 18, 2025 /PRNewswire/ -- Healthy Interactions LLC, a global leader in…

13 hours ago